Merck & Co., Inc. (BCBA:MRK)

Market Cap	265.44T
Revenue (ttm)	75.81T
Net Income (ttm)	19.55T
Shares Out	n/a
EPS (ttm)	7,728.34
PE Ratio	13.58
Forward PE	8.96
Dividend	435.90 (2.00%)
Ex-Dividend Date	Jun 13, 2025

Volume	9,478
Average Volume	7,491
Open	20,800
Previous Close	21,825
Day's Range	20,000 - 21,475
52-Week Range	16,950 - 33,375
Beta	0.40
RSI	60.61
Earnings Date	Jul 29, 2025

About Merck & Co.

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The company offers human health pharmaceutical for various areas, including oncology, vaccines, hospital acute care, cardiovascular, virology, neuroscience, and diabetes under the Keytruda, Welireg, Gardasil, ProQuad, M−M−R II, Varivax, Vaxneuvance, RotaTeq, Pneumovax 23, Bridion, Dificid, Zerbaxa, Noxafil, Winrevair, Adempas, Verquvo, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janu...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1891
• Employees: 75,000
• Stock Exchange: Buenos Aires Stock Exchange
• Ticker Symbol: MRK

Financial Performance

In 2024, Merck & Co.'s revenue was $64.17 billion, an increase of 6.74% compared to the previous year's $60.12 billion. Earnings were $17.12 billion, an increase of 4589.59%.

Financial numbers in USD